AstraZeneca's IMFINZI Combo Dramatically Cuts Bladder Cancer Recurrence and Death
A groundbreaking new treatment for muscle-invasive bladder cancer just hit the headlines, with AstraZeneca's IMFINZI (durvalumab) in combination with neoadjuvant enfortumab vedotin dramatically cutting the risk of recurrence by 49% and death by 42%. These impressive results from the VOLGA Phase III trial, unveiled at the ESMO Congress 2026, offer a significant new hope for patients who can't undergo standard cisplatin-based chemotherapy or have chosen not to.













